Clinical trials: Collecting Duct Carcinoma
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 581 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone.
- Conditions
- Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma
- Trial name
- NCT04071223
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 47 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
- Conditions
- Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma
- Trial name
- NCT03635892
- Testing
- cabozantinib, nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other…
- Conditions
- Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT04413123
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bradley A. McGregor, MD
Bellini Carcinoma, Collecting Duct Carcinoma
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
This is a single-arm, monocentric, phase II trial, enrolling patients with histological diagnosis of collecting duct carcinoma and renal medullary carcinoma with locally advanced or metastatic disease who will be treated with…
- Conditions
- Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma
- Trial name
- REPRINT (NCT06302569)
- Testing
- Pembrolizumab + Enfortumab Vedotin
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Giuseppe Procopio
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic).
- Conditions
- Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma
- Trial name
- NCT01767636
- Testing
- Pazopanib Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Collecting Duct Carcinoma
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
- Trial name
- NCT06211114
- Testing
- PD-(L)1 inhibitor, Axitinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer.
- Conditions
- Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Hereditary Papillary Renal Cell Carcinoma
- Trial name
- NCT04603365
- Testing
- Pamiparib, Temozolomide
- Sponsor
- Jonsson Comprehensive Cancer Center
Collecting Duct Carcinoma
Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)
Collect a large number of samples with certain / suspected diagnosis of collecting duct carcinoma in order to confirm the diagnosis (centralized review) and standardize according to WHO 2016 criteria Build an extensive tissue…
- Trial name
- CICERONE (NCT05372302)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collecting Duct Carcinoma (Kidney)
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic Collecting Duct Renal Cell Carcinoma
- Trial name
- BONSAI (NCT03354884)
- Testing
- cabozantinib
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collecting Duct Carcinoma (Kidney)
Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
Open-label, non-randomized, multicenter, phase II, single arm non comparative trial evaluating toxicity and efficacy of gemcitabine plus platinum salt in combination with bevacizumab in first-line setting in metastatic collecting…
- Trial name
- BEVABEL (NCT02363751)
- Testing
- Bevacizumab
- Where
- 19 sites in France
- Volunteers
- 36 people
- Sponsor
- UNICANCER